Gilead’s Magrolimab ineffective, linked to increased risk of death in MDS patients

Gilead Sciences on Friday unveiled its final analysis of the Phase III ENHANCE study, providing more details surrounding the troubled development of its blood cancer therapy magrolimab.

In the late-stage trial—which compared magrolimab against placebo in nearly 540 higher-risk myelodysplastic syndromes (HR-MDS) patients who were also receiving standard-of-care azacitidine—Gilead’s antibody resulted in an approximately 20% higher risk of death versus placebo, though this effect was not statistically significant.